WiciTech's World-First 128-Channel Liquid-Helium-Free MEG System Marvel MEG® Gains Market Approval and Secures Over RMB 100 Million in Series A+ Financing

VCBeat has learned that recently, Marvel MEG, an innovative medical device independently developed by X-Magtech—the world’s first 128-channel liquid-helium-free magnetoencephalography (MEG) system^®(Beijing Medical Device Registration Approval No. 20242070378) has been successfully approved for market launch; this product is the world's highest-channel-count liquid-helium-free magnetoencephalography (MEG) system.

As another major milestone achieved by X-Magtech in the National Key R&D Program “Development of Novel Liquid-Helium-Free Magnetoencephalography Systems” (Project No.: 2022YFC2403900), the successful approval of this product represents a significant breakthrough in China’s high-end innovative medical devices, providing a powerful tool for the diagnosis of major brain disorders and neuroscience research in China.

This Marvel MEG^®The approval and market launch of the magnetoencephalography (MEG) system have enabledX-Magtech Becomes the World’s Only Innovative Company to Receive Approval for the Market Launch of Both Liquid-Helium-Free Magnetoencephalography (MEG) and Magnetocardiography (MCG) Systems, marking the company's leapfrog development from following in the footsteps of the United States and the United Kingdom to leading the world in quantum precision measurement and medical applications.

X-Magtech Marvel MEG^®Magnetoencephalography (MEG) System

Marvel MEG^®The magnetoencephalography (MEG) system is based on X-Magtech’s fully independent intellectual property rights in quantum precision magnetic field measurement technology—atomic magnetometers. It comprises a high-density MEG detection array with up to 128 channels and no crosstalk, achieving a sensitivity of 10 fT (1 fT = 10^-15Tesla) magnitude, detecting and displaying the magnetic field signals generated by the electrical activity of neural tissue in the brain in a non-invasive manner to perform brain functional imaging. Due to its combination of high temporal resolution and high spatial resolution, as well as being non-invasive, radiation-free, and requiring no contrast agents, Marvel MEG^®Magnetoencephalography (MEG) is an ideal brain functional imaging technology, providing novel approaches for clinical and research applications such as epilepsy diagnosis and lesion localization, mapping and assessment of functional brain areas, targeting and efficacy evaluation in neuromodulation, as well as the assessment of cognitive disorders, psychiatric disorders, and brain development.

Marvel MEG^®The magnetoencephalography (MEG) system previously obtained approval as an innovative medical device in Beijing and completed clinical studies at Beijing Tiantan Hospital. Its efficacy and safety were validated through comparative studies with commercially available superconducting MEG systems. In addition to Beijing Tiantan Hospital, X-Magtech has established collaborative partnerships with leading institutions such as Xuanwu Hospital, Wuhan Tongji Hospital, Shandong Provincial Hospital, and Dongzhimen Hospital, where the system has been widely deployed, yielding a series of breakthrough achievements.

Marvel MEG^®Fusion Results of Magnetoencephalography (MEG) Mapping of the Right-Hand Motor Area in Healthy Subjects with 7.0T Magnetic Resonance Imaging

Marvel MEG^®Magnetoencephalography: Brain Network Connectivity Maps in the Delta, Alpha, and Beta Frequency Bands for Healthy Individuals at Rest

X-Magtech also announced the completion of its over RMB 100 million Series A+ financing round, which was led byBeijing Robotics Industry FundLead Investor,CAS Star,Existing ShareholdersLongma Peak Venture Capital,Zhongguancun Science City,CMBC International, Yarui CapitalFollow-on investment. To date, X-Magtech has completed five rounds of financing totaling over RMB 300 million in the four years since its establishment.

It is reported that,X-Magtech and Fosun Medical Devices have recently reached a comprehensive strategic cooperation,The two parties will engage in systematic and in-depth collaboration across scientific research and clinical cooperation in quantum precision magnetometry and healthcare, as well as market development and brand promotion, to jointly advance the application and commercialization of quantum magnetic sensing technology in the field of biomagnetic imaging.

X-Magtech is dedicated to the research, development, and manufacturing of high-end medical equipment for biomagnetic imaging, aiming to integrate quantum technology into the healthcare industry. The company’s core technology platform for quantum-precision magnetic field measurement has reached a world-leading level, establishing a series of core technologies and mass production capabilities in atomic vapor cell fabrication, optoelectronic integrated chip manufacturing and packaging/testing, high-performance magnetic shielding design and manufacturing, and precise active magnetic field control. In 2024, the annual production capacity of its atomic magnetometers exceeded 3,000 units.

At the same time, targeting the needs for diagnosis and scientific research of major cardiovascular and cerebrovascular diseases, the company has taken the lead in commercializing quantum technology in medical scenarios by independently developing two high-end innovative medical devices: a magnetocardiography (MCG) system and a magnetoencephalography (MEG) system. Since obtaining the medical device registration certificate, its helium-free MCG system has beenInstalled and utilized by more than ten hospitals, including Beijing Anzhen Hospital, Peking Union Medical College Hospital, Xiangya Hospital, Wuhan Tongji Hospital, and Guangdong Provincial People's Hospital, the system has been applied in over 30,000 patient cases. Dozens of clinical studies have demonstrated its significant value in areas such as stable coronary artery disease, coronary microcirculation disorders, screening of healthy populations, long-term monitoring following pharmacological intervention or stent implantation, and arrhythmias.

In the future, X-Magtech will continue to focus on clinical needs, steadily increase R&D investment, optimize product performance, expand application scenarios, enrich its product portfolio, and promote the widespread adoption of quantum precision measurement technology in healthcare and brain science. In doing so, the company aims to contribute to the development of new quality productive forces in China’s quantum technology and biomedical sectors.

Zhu Fangwen, Managing Director of Shougang FundIt stated: “As the lead investor in this round, the Beijing Robotics Industry Fund is optimistic about X-Magtech’s development potential, its team’s outstanding R&D background, and comprehensive experience in product commercialization. The Fund recognizes the strategic positioning of magnetic field sensing technology in fields such as brain-controlled robotics and brain-computer interfaces (BCI), and also sees strong clinical value and commercial prospects for the company’s technology in applications like magnetoencephalography (MEG) and magnetocardiography (MCG). X-Magtech is a global leading platform company in quantum detection technology. Its unique magnetic field sensing technology has broad application scenarios in robotics across medical, military, and industrial inspection sectors, serving as a critical upstream foundational technology for the robotics industry. Furthermore, as an excellent non-invasive BCI modality, magnetoencephalography can provide significant support for future robotic technologies such as brain-controlled robots. In the future, the Fund will continue to support X-Magtech in product and technology upgrades and commercial expansion, accompanying the company’s growth and contributing to the high-quality development of Beijing’s robotics industry.””

Mi Lei, Founding Partner of CAS Starstated: “The atomic magnetometer independently developed by X-Magtech is a typical example of the integrated application of photonics and quantum technologies, belonging to foundational meta-technologies. Both the sensor itself and the magnetocardiography (MCG) and magnetoencephalography (MEG) systems utilizing these sensors have reached world-leading levels, enabling traditional liquid-helium-based superconducting medical equipment to enter a phase of large-scale adoption without liquid helium. Adhering to first-principles thinking, the team is continuously expanding the application scenarios for atomic magnetometers. We are highly optimistic about X-Magtech’s long-term performance in the two major sectors of quantum technology and life sciences, and look forward to the company achieving even greater accomplishments in the future.””

Cai Bin, Founder of X-Magtechstated: “The continued strong support from the Robotics Fund, CAS Star, and our existing shareholders will accelerate the deployment of our quantum precision measurement technology in the biomedical sector. This will leverage our advantages in quantum precision magnetometry to achieve precise and early diagnosis of major cardiac and neurological diseases, while also supporting development in strategic fields such as brain science and brain-computer interfaces. Our strategic partnership with Fosun Medical Devices will further expedite the clinical application and promotion of our products. X-Magtech will continue to innovate, upholding its responsibility and mission as a leader in quantum precision magnetometry, and realizing its vision of ‘Quantum Sensing for a Better World.’”